Cogent Biosciences Inc
$ 31.25
-0.35%
19 May - close price
- Market Cap 5,358,420,000 USD
- Current Price $ 31.25
- High / Low $ 31.88 / 30.87
- Stock P/E N/A
- Book Value 3.18
- EPS -2.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.86 %
- 52 Week High 43.73
- 52 Week Low 4.75
About
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$54.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-17 | 2025-11-07 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-07 | 2024-02-26 | 2023-11-02 | 2023-08-08 |
| Reported EPS | -0.53 | -0.5628 | -0.5 | -1.27 | -0.5249 | -0.09 | -0.6412 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 |
| Estimated EPS | -0.5016 | -0.5101 | -0.5217 | -0.5867 | -0.5771 | -0.5837 | -0.5664 | -0.56 | -0.52 | -0.56 | -0.5 | -0.54 |
| Surprise | -0.0284 | -0.0527 | 0.0217 | -0.6833 | 0.0522 | 0.4937 | -0.0748 | -0.03 | -0.1 | -0.07 | -0.14 | -0.05 |
| Surprise Percentage | -5.6619% | -10.3313% | 4.1595% | -116.465% | 9.0452% | 84.5811% | -13.2062% | -5.3571% | -19.2308% | -12.5% | -28% | -9.2593% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: COGT
2026-05-16 03:38:57
Cogent Biosciences' (COGT) valuation is under review following new APEX and JAK2 data presentations, despite a significant multi-year shareholder return. The company's Price to Book (P/B) ratio of 10.8x is considerably higher than industry averages, reflecting investor confidence in its clinical pipeline rather than current unprofitable financials. While the upcoming data presentation could be a catalyst, the high P/B suggests that the valuation is largely speculative and sensitive to trial outcomes and market sentiment.
2026-05-15 09:09:50
Cogent Biosciences (COGT) has gained attention after announcing upcoming APEX trial data for bezuclastinib at the European Hematology Association 2026 Congress. Despite a significant multi-year shareholder return, the stock has seen a recent pullback. The article questions whether Cogent is undervalued, noting its high Price-to-Book ratio of 10.8x compared to industry averages and its current unprofitability, suggesting its valuation heavily relies on future clinical pipeline success.
2026-05-15 01:09:47
A Schedule 13G/A filing reveals that Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn collectively beneficially own 9,043,903 shares of Cogent Biosciences (NASDAQ: COGT) common stock. This represents 5.29% of the class as of March 31, 2026. The filing indicates shared voting and dispositive power attributed to Deerfield Partners, L.P.
2026-05-13 00:09:43
This page provides access to Cogent Biosciences Inc (COGT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. It details the company's focus on precision therapies and notes recent filings cover financial results, business updates, clinical data, and corporate governance matters. StockTitan tracks 43 COGT filings, with the most recent being on July 8, 2025.
2026-05-12 14:09:43
Cogent Biosciences announced that data from its pivotal APEX trial for bepranemab in patients with advanced systemic mastocytosis will be presented at the EHA Congress 2026. The company will also provide an update on its selective JAK2 V617F inhibitor program, CGT2428, aimed at treating myeloproliferative neoplasms. These presentations highlight Cogent's advancements in oncology and rare disease drug development.
2026-05-12 13:39:17
Cogent Biosciences will present pivotal data from its APEX trial in Advanced Systemic Mastocytosis and preclinical data from its JAK2 V617F program at the European Hematology Association (EHA) 2026 Congress. The APEX trial results for bezuclastinib in Advanced Systemic Mastocytosis will be featured in an oral presentation, marking the company's third oral presentation of pivotal data for this drug. Additionally, a poster will detail preclinical findings for a novel, selective JAK2 V617F mutant-selective inhibitor.
